685 related articles for article (PubMed ID: 15585611)
1. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
4. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer.
Arya M; Chao D; Patel HR
Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up.
Peres E; Abidi MH; Mellon-Reppen S; Klein J; Braun T; Abella E; Dansey R
J Immunother; 2007; 30(5):562-6. PubMed ID: 17589297
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.
Abe Y; Ito T; Baba E; Nagafuji K; Kawabe K; Choi I; Arita Y; Miyamoto T; Teshima T; Nakano S; Harada M
Pancreas; 2009 Oct; 38(7):815-9. PubMed ID: 19696692
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
Rini BI; Zimmerman T; Stadler WM; Gajewski TF; Vogelzang NJ
J Clin Oncol; 2002 Apr; 20(8):2017-24. PubMed ID: 11956260
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
11. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Castermans E; Baron F; Willems E; Schaaf-Lafontaine N; Meuris N; Gothot A; Vanbellighen JF; Herens C; Seidel L; Geenen V; Cheynier R; Beguin Y
Haematologica; 2008 Feb; 93(2):240-7. PubMed ID: 18223286
[TBL] [Abstract][Full Text] [Related]
12. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
Kersting S; Verdonck LF
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1312-6. PubMed ID: 18940687
[TBL] [Abstract][Full Text] [Related]
13. Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.
Fernández-Avilés F; Urbano-Ispizua A; Aymerich M; Rovira M; Martínez C; Talarn C; Jiménez M; Carreras E; Montserrat E
Exp Hematol; 2003 Oct; 31(10):934-40. PubMed ID: 14550809
[TBL] [Abstract][Full Text] [Related]
14. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
Tykodi SS; Fujii N; Vigneron N; Lu SM; Mito JK; Miranda MX; Chou J; Voong LN; Thompson JA; Sandmaier BM; Cresswell P; Van den Eynde B; Riddell SR; Warren EH
Clin Cancer Res; 2008 Aug; 14(16):5260-9. PubMed ID: 18698046
[TBL] [Abstract][Full Text] [Related]
15. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
Childs RW; Clave E; Tisdale J; Plante M; Hensel N; Barrett J
J Clin Oncol; 1999 Jul; 17(7):2044-9. PubMed ID: 10561256
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
[TBL] [Abstract][Full Text] [Related]
18. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study.
Ishiyama K; Takami A; Suzuki S; Konaka H; Namiki M; Ooi A; Nakao S
Jpn J Clin Oncol; 2009 Dec; 39(12):807-12. PubMed ID: 19770130
[TBL] [Abstract][Full Text] [Related]
19. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
[TBL] [Abstract][Full Text] [Related]
20. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
